Beta-adrenergic blockade does not prevent polycythemia or decrease in plasma volume in men at 4300 m altitude. 1998

R F Grover, and M A Selland, and R G McCullough, and T E Dahms, and E E Wolfel, and G E Butterfield, and J T Reeves, and J E Greenleaf
Cardiovascular Pulmonary Research Laboratory, University of Colorado Health Sciences Center, Denver 80262, USA.

When humans ascend to high altitude (ALT) their plasma volume (PV) and total blood volume (BV) decrease during the first few days. With continued residence over several weeks, the hypoxia-induced stimulation of erythropoietin increases red cell production which tends to restore BV. Because hypoxia also activates the beta-adrenergic system, which stimulates red blood cell production, we investigated the effect of adrenergic beta-receptor inhibition with propranolol on fluid volumes and the polycythemic response in 11 healthy unacclimatized men (21-33 years old exposed to an ALT of 4300 m (barometric pressure 460 Torr) for 3 weeks on Pikes Peak, Colorado. PV was determined by the Evans blue dye method (PVEB), BV by the carbon monoxide method (BVCO), red cell volume (RCV) was calculated from hematocrit (Hct) and BVCO, and serum erythropoietin concentration ([EPO]) and reticulocyte count, were also determined. All determinations were made at sea level and after 9-11 (ALT-10) and 19-20 (ALT-20) days at ALT. At sea level and ALT, six men received propranolol (pro, 240 mg x day[-1]), and five received a placebo (pla). Effective beta-blockade did not modify the mean (SE) maximal values of [EPO] [pla: 24.9 (3.5) vs pro: 24.5 (1.5) mU x ml(-1)] or reticulocyte count [pla: 2.7 (0.7) vs pro: 2.2 (0.5)%]; nor changes in PVEB [pla: -15.8 (3.8) vs pro: -19.9 (2.8)%], RCVCO [pla: +7.0 (6.7) vs pro: + 10.1 (6.1)%], or BVCO [pla: -7.3 (2.3) vs pro: -7.1 (3.9)%]. In the absence of weight loss, a redistribution of body water with no net loss is implied. Hence, activation of the beta-adrenergic system did not appear to affect the hypovolemic or polycythemic responses that occurred during 3 weeks at 4300 m ALT in these subjects.

UI MeSH Term Description Entries
D008297 Male Males
D010953 Plasma Volume Volume of PLASMA in the circulation. It is usually measured by INDICATOR DILUTION TECHNIQUES. Blood Plasma Volume,Blood Plasma Volumes,Plasma Volumes,Volume, Blood Plasma,Volume, Plasma,Volumes, Blood Plasma,Volumes, Plasma
D011086 Polycythemia An increase in the total red cell mass of the blood. (Dorland, 27th ed) Erythrocytosis,Erythrocytoses,Polycythemias
D011433 Propranolol A widely used non-cardioselective beta-adrenergic antagonist. Propranolol has been used for MYOCARDIAL INFARCTION; ARRHYTHMIA; ANGINA PECTORIS; HYPERTENSION; HYPERTHYROIDISM; MIGRAINE; PHEOCHROMOCYTOMA; and ANXIETY but adverse effects instigate replacement by newer drugs. Dexpropranolol,AY-20694,Anaprilin,Anapriline,Avlocardyl,Betadren,Dociton,Inderal,Obsidan,Obzidan,Propanolol,Propranolol Hydrochloride,Rexigen,AY 20694,AY20694,Hydrochloride, Propranolol
D001810 Blood Volume Volume of circulating BLOOD. It is the sum of the PLASMA VOLUME and ERYTHROCYTE VOLUME. Blood Volumes,Volume, Blood,Volumes, Blood
D004920 Erythropoiesis The production of red blood cells (ERYTHROCYTES). In humans, erythrocytes are produced by the YOLK SAC in the first trimester; by the liver in the second trimester; by the BONE MARROW in the third trimester and after birth. In normal individuals, the erythrocyte count in the peripheral blood remains relatively constant implying a balance between the rate of erythrocyte production and rate of destruction. Erythropoieses
D004921 Erythropoietin Glycoprotein hormone, secreted chiefly by the KIDNEY in the adult and the LIVER in the FETUS, that acts on erythroid stem cells of the BONE MARROW to stimulate proliferation and differentiation.
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000319 Adrenergic beta-Antagonists Drugs that bind to but do not activate beta-adrenergic receptors thereby blocking the actions of beta-adrenergic agonists. Adrenergic beta-antagonists are used for treatment of hypertension, cardiac arrhythmias, angina pectoris, glaucoma, migraine headaches, and anxiety. Adrenergic beta-Antagonist,Adrenergic beta-Receptor Blockader,Adrenergic beta-Receptor Blockaders,beta-Adrenergic Antagonist,beta-Adrenergic Blocker,beta-Adrenergic Blocking Agent,beta-Adrenergic Blocking Agents,beta-Adrenergic Receptor Blockader,beta-Adrenergic Receptor Blockaders,beta-Adrenoceptor Antagonist,beta-Blockers, Adrenergic,beta-Adrenergic Antagonists,beta-Adrenergic Blockers,beta-Adrenoceptor Antagonists,Adrenergic beta Antagonist,Adrenergic beta Antagonists,Adrenergic beta Receptor Blockader,Adrenergic beta Receptor Blockaders,Adrenergic beta-Blockers,Agent, beta-Adrenergic Blocking,Agents, beta-Adrenergic Blocking,Antagonist, beta-Adrenergic,Antagonist, beta-Adrenoceptor,Antagonists, beta-Adrenergic,Antagonists, beta-Adrenoceptor,Blockader, Adrenergic beta-Receptor,Blockader, beta-Adrenergic Receptor,Blockaders, Adrenergic beta-Receptor,Blockaders, beta-Adrenergic Receptor,Blocker, beta-Adrenergic,Blockers, beta-Adrenergic,Blocking Agent, beta-Adrenergic,Blocking Agents, beta-Adrenergic,Receptor Blockader, beta-Adrenergic,Receptor Blockaders, beta-Adrenergic,beta Adrenergic Antagonist,beta Adrenergic Antagonists,beta Adrenergic Blocker,beta Adrenergic Blockers,beta Adrenergic Blocking Agent,beta Adrenergic Blocking Agents,beta Adrenergic Receptor Blockader,beta Adrenergic Receptor Blockaders,beta Adrenoceptor Antagonist,beta Adrenoceptor Antagonists,beta Blockers, Adrenergic,beta-Antagonist, Adrenergic,beta-Antagonists, Adrenergic,beta-Receptor Blockader, Adrenergic,beta-Receptor Blockaders, Adrenergic
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults

Related Publications

R F Grover, and M A Selland, and R G McCullough, and T E Dahms, and E E Wolfel, and G E Butterfield, and J T Reeves, and J E Greenleaf
February 1994, Journal of applied physiology (Bethesda, Md. : 1985),
R F Grover, and M A Selland, and R G McCullough, and T E Dahms, and E E Wolfel, and G E Butterfield, and J T Reeves, and J E Greenleaf
April 2019, Medicine and science in sports and exercise,
R F Grover, and M A Selland, and R G McCullough, and T E Dahms, and E E Wolfel, and G E Butterfield, and J T Reeves, and J E Greenleaf
February 1984, Journal of hypertension,
R F Grover, and M A Selland, and R G McCullough, and T E Dahms, and E E Wolfel, and G E Butterfield, and J T Reeves, and J E Greenleaf
January 1989, Psychosomatic medicine,
R F Grover, and M A Selland, and R G McCullough, and T E Dahms, and E E Wolfel, and G E Butterfield, and J T Reeves, and J E Greenleaf
January 2008, High altitude medicine & biology,
R F Grover, and M A Selland, and R G McCullough, and T E Dahms, and E E Wolfel, and G E Butterfield, and J T Reeves, and J E Greenleaf
January 1991, European journal of applied physiology and occupational physiology,
R F Grover, and M A Selland, and R G McCullough, and T E Dahms, and E E Wolfel, and G E Butterfield, and J T Reeves, and J E Greenleaf
November 1978, Infection and immunity,
R F Grover, and M A Selland, and R G McCullough, and T E Dahms, and E E Wolfel, and G E Butterfield, and J T Reeves, and J E Greenleaf
March 2004, Clinical science (London, England : 1979),
R F Grover, and M A Selland, and R G McCullough, and T E Dahms, and E E Wolfel, and G E Butterfield, and J T Reeves, and J E Greenleaf
December 1971, American heart journal,
R F Grover, and M A Selland, and R G McCullough, and T E Dahms, and E E Wolfel, and G E Butterfield, and J T Reeves, and J E Greenleaf
January 2008, Medicine and science in sports and exercise,
Copied contents to your clipboard!